Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Vical Incorporated (Nasdaq:VICL) announced today that the company's TransVax™ cytomegalovirus (CMV) vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant (HCT) recipients. Richard T. Kenney, M.D., Vical's Vice President of Clinical Development, is presenting the encouraging preliminary data today at the World Vaccine Congress (Washington – April 19-22).

"We were excited to see that our TransVax™ vaccine was able to enhance both T-cell and antibody responses to the encoded CMV antigens through the final 12-month data point," said Dr. Kenney, "and we are excited to see how these responses impact viral control. We also saw an encouraging boost in both T-cell and antibody responses after the fourth injection, which could prove important in controlling late-onset CMV reactivation. We expect to complete our analysis of the final trial data and report on our full evaluation of viral load and clinical endpoints in the third quarter."